FY2024 EPS Estimates for Outlook Therapeutics, Inc. (NASDAQ:OTLK) Boosted by HC Wainwright

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Research analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Outlook Therapeutics in a research report issued on Thursday, August 15th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($4.04) for the year, up from their previous estimate of ($4.26). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($4.08) per share. HC Wainwright also issued estimates for Outlook Therapeutics’ Q4 2024 earnings at ($0.89) EPS, Q1 2025 earnings at ($0.99) EPS, Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($2.24) EPS and FY2026 earnings at ($0.41) EPS.

Separately, Chardan Capital reissued a “buy” rating and issued a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.55.

Outlook Therapeutics Stock Down 0.8 %

OTLK stock opened at $7.10 on Monday. The firm has a market capitalization of $166.21 million, a PE ratio of -0.62 and a beta of 0.71. Outlook Therapeutics has a twelve month low of $4.00 and a twelve month high of $29.20. The stock’s 50 day moving average is $7.68 and its 200-day moving average is $8.05.

Hedge Funds Weigh In On Outlook Therapeutics

Several institutional investors have recently added to or reduced their stakes in OTLK. Rosalind Advisors Inc. bought a new position in shares of Outlook Therapeutics during the 1st quarter valued at approximately $3,723,000. LVW Advisors LLC purchased a new position in Outlook Therapeutics in the second quarter valued at approximately $352,000. Great Point Partners LLC increased its position in Outlook Therapeutics by 15.0% in the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after buying an additional 221,510 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Outlook Therapeutics in the second quarter valued at $232,000. Finally, AQR Capital Management LLC purchased a new position in shares of Outlook Therapeutics during the 2nd quarter valued at $75,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.